AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3001780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐g marihuana cigarette containing 1.83% delta 9‐tetrahydrocannabinol (THC)
Number of subjects: 10
Study 3001780 — intervention group
Group type: COMPARATOR
Intervention: 1‐g marihuana placebo cigarette
Number of subjects: 10
Study 30031600 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Web‐based decision aid
Number of subjects: 90
Study 30031600 — intervention group
Group type: COMPARATOR
Intervention: Usual care (an informational brochure)
Number of subjects: 90
Study 29616749 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic therapy: 10 mT, 50 Hz
Number of subjects: 106
Study 29616749 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic therapy: 5 mT, 50 Hz
Number of subjects: 106
Study 29616749 — intervention group
Group type: COMPARATOR
Intervention: Placebo magnetic therapy
Number of subjects: 106
Study 29616749 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation: 49.2 μT, 195 Hz
Number of subjects: 106
Study 29616749 — intervention group
Group type: COMPARATOR
Intervention: Placebo magnetic stimulation
Number of subjects: 106
Study 26860514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 215
Study 26860514 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 215
Study 26860514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (6-9 points)
Number of subjects: 215
Study 25844704 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (n=10)
Number of subjects: 20
Study 25844704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 20
Study 25844704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after TENS disabled
Number of subjects: 20
Study 23926420 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dihydroergotamine (MAP0004)
Number of subjects: 24
Study 23926420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dihydroergotamine (IV DHE)
Number of subjects: 24
Study 23926420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21879942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass media campaign
Number of subjects: 1472
Study 19378358 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release of the A1 pulley
Number of subjects: 0
Study 19378358 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 0
Study 17158412 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (2.1 g/d)
Number of subjects: 90
Study 17158412 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 90
Study 17158412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 14634736 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-free image-guided surgical navigation system for acetabular cup placement
Number of subjects: 256
Study 11062277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintensive stroke unit care with a care continuum
Number of subjects: 249
Study 11062277 — intervention group
Group type: COMPARATOR
Intervention: Conventional care in general medical wards
Number of subjects: 249
Study 11062277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild stroke
Number of subjects: 249
Study 11062277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate stroke
Number of subjects: 249
Study 11062277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe stroke
Number of subjects: 249
Study 9146778 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 406
Study 9146778 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 3 consecutive days each week
Number of subjects: 406
Study 9146778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 7526001 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoechoic cancers
Number of subjects: 417
Study 7526001 — intervention group
Group type: COMPARATOR
Intervention: Hypoechoic cancers
Number of subjects: 417
Study 3110845 — intervention group
Group type: EXPERIMENTAL
Intervention: DGAVP (desglycinamide‐arginine‐vasopressin) administered intranasally, increasing dose from 0.1 mg on day 1 to 10.0 mg on day 5.
Number of subjects: 20
Study 3110845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 29643338 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood pressure (systolic blood pressure)
Number of subjects: 339224
Study 29643338 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood pressure (diastolic blood pressure)
Number of subjects: 339224
Study 29643338 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted QRS traits
Number of subjects: 339224
Study 26766930 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg TeaCrine® (LD)
Number of subjects: 60
Study 26766930 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg TeaCrine® (HD)
Number of subjects: 60
Study 26766930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study 24261584 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of twice weekly group exercise training plus education
Number of subjects: 267
Study 24261584 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 267
Study 22391106 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SRI antidepressant)
Number of subjects: 811
Study 22391106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (tricyclic antidepressant)
Number of subjects: 811
Study 22391106 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 811
Study 20731499 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants experiencing anger
Number of subjects: 0
Study 20731499 — intervention group
Group type: COMPARATOR
Intervention: Participants with low expectancy of encountering guns
Number of subjects: 0
Study 20731499 — intervention group
Group type: COMPARATOR
Intervention: Participants with high expectancy of encountering guns
Number of subjects: 0
Study 20731499 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the 5th study
Number of subjects: 0
Study 18685511 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formulation A (3 probiotic strains and FOS)
Number of subjects: 721
Study 18685511 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formulation C (5 probiotics and FOS)
Number of subjects: 721
Study 18685511 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formulation D (5 probiotics and GOS)
Number of subjects: 721
Study 18685511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study 16966680 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing early education programs or program components; specific interventions not detailed.
Number of subjects: 0
Study 14525568 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anti-inflammatory gel (NSAID)
Number of subjects: 386
Study 14525568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 386
Study 14525568 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 386
Study 10655976 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread enriched with free soyabean-oil sterols (0.8 g/d)
Number of subjects: 76
Study 10655976 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread enriched with sheanut-oil sterols (3.3 g/d)
Number of subjects: 76
Study 10655976 — intervention group
Group type: COMPARATOR
Intervention: Control spread (not fortified)
Number of subjects: 76
Study 8876415 — intervention group
Group type: EXPERIMENTAL
Intervention: CCU sounds audiotape throughout the night
Number of subjects: 60
Study 8876415 — intervention group
Group type: COMPARATOR
Intervention: Quiet environment (audiotape of CCU sounds withheld)
Number of subjects: 60
Study 1304727 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg of oral triazolam
Number of subjects: 30
Study 1304727 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg of oral clonidine
Number of subjects: 30
Study 1304727 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of oral triazolam and 0.75 mg of intrathecal phenylephrine
Number of subjects: 30
Study 6089652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal human interferon-alpha 2 (HuIFN-alpha 2) 10(7) IU/day
Number of subjects: 304
Study 6089652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 6089652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal human interferon-alpha 2 (HuIFN-alpha 2)
Number of subjects: 304
Study 26362259 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher Help for ADHD treatment group
Number of subjects: 58
Study 26362259 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 30576315 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial patterned direct current stimulation during gait
Number of subjects: 15
Study 30576315 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during gait
Number of subjects: 15
Study 30576315 — intervention group
Group type: COMPARATOR
Intervention: Anodal transcranial patterned direct current stimulation during rest
Number of subjects: 15
Study 27374361 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (AlGaAs infrared laser 808 nm)
Number of subjects: 24
Study 27374361 — intervention group
Group type: COMPARATOR
Intervention: Mock laser therapy (device powered off)
Number of subjects: 24
Study 25140469 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery (LITA) for LAD and free right internal thoracic artery (RITA) for circumflex in Group-1 (G-1)
Number of subjects: 100
Study 25140469 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery (RITA) pedicled to LAD and left internal thoracic artery (LITA) pedicled to circumflex in Group-2 (G-2)
Number of subjects: 100
Study 22221980 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance planning intervention (home visits by a facilitator, group information session about My Preferences)
Number of subjects: 240
Study 22221980 — intervention group
Group type: COMPARATOR
Intervention: Control group (three monthly workshops promoting healthy behaviors)
Number of subjects: 240
Study 19558948 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-choline PET/CT
Number of subjects: 38
Study 19558948 — intervention group
Group type: COMPARATOR
Intervention: (18)F-FDG PET/CT
Number of subjects: 38
Study 17681825 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt placement
Number of subjects: 96
Study 17681825 — intervention group
Group type: COMPARATOR
Intervention: No shunt placement
Number of subjects: 96
Study 15854939 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuits
Number of subjects: 30
Study 15854939 — intervention group
Group type: COMPARATOR
Intervention: Noncoated extracorporeal circuits
Number of subjects: 30
Study 11961147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular gamma radiation with iridium‐192
Number of subjects: 120
Study 11961147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonradioactive seeds)
Number of subjects: 120
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe mitral regurgitation (n=1)
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on therapy (n=13)
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild mitral regurgitation (n=6)
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate mitral regurgitation (n=5)
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients referred for mitral valve replacement (n=8)
Number of subjects: 35
Study 9591766 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=13)
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with end-systolic diameter
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with end-diastolic diameter
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with left ventricular wall thickness
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with left atrial dimension
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with percent fractional shortening
Number of subjects: 35
Study 9591766 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with left ventricular mass/body surface area
Number of subjects: 35
Study 7611750 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 250 mg/m2 of l‐leucovorin and 600 mg/m2 of 5‐fluorouracil weekly
Number of subjects: 28
Study 7611750 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: 100 mg/m2 of l‐leucovorin and 370 mg/m2 of 5‐fluorouracil for 5 consecutive days
Number of subjects: 28
Study 7611750 — intervention group
Group type: COMPARATOR
Intervention: Arm C: 10 mg/m2 of l‐leucovorin and 370 mg/m2 of 5‐fluorouracil for 5 consecutive days
Number of subjects: 28
Study 2361638 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole tablets 500 mg 3 times daily for 10 days
Number of subjects: 42
Study 2361638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen)
Number of subjects: 42
Study 2361638 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (repeated treatments, once or twice)
Number of subjects: 42
Study 2361638 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after successful treatment
Number of subjects: 42
Study 2361638 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatment
Number of subjects: 42
Study 58199 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin alone
Number of subjects: 84
Study 58199 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and D.H.E.
Number of subjects: 84
Study 58199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 84
Study 58199 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin alone and Heparin and D.H.E.
Number of subjects: 84
Study 29562851 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization Adult ADHD Self‐Report Scale screener with standard generic feedback
Number of subjects: 157
Study 29562851 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 157
Study 26582579 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural mineral water (500 mL)
Number of subjects: 106
Study 26582579 — intervention group
Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 106
Study 26053679 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antihelminthic treatment with 400 mg albendazole
Number of subjects: 98
Study 26053679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 23786864 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 24
Study 23786864 — intervention group
Group type: COMPARATOR
Intervention: Late enteral nutrition
Number of subjects: 24
Study 20888884 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 (nanofill composite)
Number of subjects: 41
Study 20888884 — intervention group
Group type: EXPERIMENTAL
Intervention: Esthet‐X (nanohybrid composite)
Number of subjects: 41
Study 20888884 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250 (control composite)
Number of subjects: 41
Study 17698301 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the Mother‐Infant Transaction Program
Number of subjects: 136
Study 17698301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 16432294 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg via Easyhaler
Number of subjects: 67
Study 16432294 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 microg via Aerolizer
Number of subjects: 67
Study 16432294 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 48 microg via Easyhaler
Number of subjects: 67
Study 16432294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 12967078 — intervention group
Group type: EXPERIMENTAL
Intervention: Z100/Single Bond
Number of subjects: 60
Study 12967078 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom/Stae
Number of subjects: 60
Study 12967078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer/Primer
Number of subjects: 60
Study 12967078 — intervention group
Group type: EXPERIMENTAL
Intervention: Durafill/Durafill Bond
Number of subjects: 60
Study 10710871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Ofloxacin otic solution (OFLX) 6 drops twice daily
Number of subjects: 80
Study 10710871 — intervention group
Group type: COMPARATOR
Intervention: Oral Amoxycillin 500 mg three times daily plus 1% Chloramphenicol ear drop at 3 drops three times daily (AMOX + CRP)
Number of subjects: 80
Study 8703458 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus saline
Number of subjects: 56
Study 8703458 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus succinylcholine
Number of subjects: 56
Study 8703458 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamylal plus succinylcholine
Number of subjects: 56
Study 8703458 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol without succinylcholine
Number of subjects: 56
Study 1286717 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the posterior parietal cortex, applied 80 ms after target movement in 70% of trials.
Number of subjects: 0
Study 1286717 — intervention group
Group type: COMPARATOR
Intervention: Control, unstimulated trials.
Number of subjects: 0
Study 3872082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous neural stimulation (TNS)
Number of subjects: 90
Study 3872082 — intervention group
Group type: COMPARATOR
Intervention: Placebo unit
Number of subjects: 90
Study 3872082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TNS unit)
Number of subjects: 90
Study 31963702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified formula with dairy-based microencapsulated high DHA tuna oil powder
Number of subjects: 60
Study 31963702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified formula with allergenic-free microencapsulated high DHA tuna oil powder
Number of subjects: 60
Study 31963702 — intervention group
Group type: COMPARATOR
Intervention: Unfortified formula plus high DHA tuna oil
Number of subjects: 60
Study 31963702 — intervention group
Group type: COMPARATOR
Intervention: Unfortified formula
Number of subjects: 60
Study 30397735 — intervention group
Group type: EXPERIMENTAL
Intervention: iRoot SP sealer
Number of subjects: 160
Study 30397735 — intervention group
Group type: COMPARATOR
Intervention: AH Plus sealer
Number of subjects: 160
Study 28002181 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 16
Study 28002181 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (no caffeine)
Number of subjects: 16
Study 25959878 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable collagen membrane (Bio-Gide, Geistlich Pharma AG) placement after extraction of L3M
Number of subjects: 60
Study 25959878 — intervention group
Group type: COMPARATOR
Intervention: Control group (only suture) after extraction of L3M
Number of subjects: 60
Study 24377413 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Number of subjects: 75
Study 24377413 — intervention group
Group type: COMPARATOR
Intervention: Usual-care program
Number of subjects: 75
Study 21965459 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (EEF)
Number of subjects: 59
Study 21965459 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral feeding (DEF)
Number of subjects: 59
Study 20671225 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin combined with benazepril-valsartan therapy
Number of subjects: 186
Study 20671225 — intervention group
Group type: COMPARATOR
Intervention: Benazepril-valsartan therapy alone
Number of subjects: 186
Study 17438421 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) instrument 1
Number of subjects: 20
Study 17438421 — intervention group
Group type: COMPARATOR
Intervention: Stratus optical coherence tomography (OCT) instrument 2
Number of subjects: 20
Study 19810298 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate powder, equivalent to 20 mg elemental zinc
Number of subjects: 242
Study 19810298 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 242
Study 12476650 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stent (drug-eluting stent)
Number of subjects: 266
Study 12476650 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-drug-eluting stent)
Number of subjects: 266
Study 12476650 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stent (TAXUS-I trial)
Number of subjects: 266
Study 12476650 — intervention group
Group type: COMPARATOR
Intervention: Control group (TAXUS-I trial)
Number of subjects: 266
Study 12476650 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stents (ASPECT and ELUTES trials)
Number of subjects: 266
Study 12476650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated stents (RAVEL and SIRIUS trials)
Number of subjects: 266
Study 10467200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical evacuation
Number of subjects: 268
Study 10467200 — intervention group
Group type: COMPARATOR
Intervention: No neurosurgical evacuation (Control)
Number of subjects: 268
Study 7600552 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory patient education (two structured teaching interventions incorporating sensory and procedural information)
Number of subjects: 50
Study 7600552 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 50
Study 7600552 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory patient education
Number of subjects: 50